Exact Sciences Analysts Slash Their Forecasts After Q2 Results
Portfolio Pulse from Avi Kapoor
Exact Sciences Corporation (NASDAQ:EXAS) reported better-than-expected Q2 results, with losses of 9 cents per share and sales of $699.264 million. Despite the positive results, analysts have lowered their price targets. The company also announced an exclusive license agreement with TwinStrand Biosciences.
August 01, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences reported better-than-expected Q2 results, with losses of 9 cents per share and sales of $699.264 million. Despite the positive results, analysts have lowered their price targets. The company also announced an exclusive license agreement with TwinStrand Biosciences.
Exact Sciences reported strong Q2 results, beating both earnings and revenue estimates. This positive performance led to a significant 23.2% increase in share price. However, analysts have lowered their price targets, which may temper some of the bullish sentiment. The exclusive license agreement with TwinStrand Biosciences is also a positive development, potentially adding value in the long term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100